Inventor
Yan Chen
Inventor
Foster City, CA, US
Overview
Patents· 131 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%
A61KPreparations for medical, dental or toiletry purposes20%
C07DHeterocyclic compounds16%
C07KPeptides9%
C12NMicroorganisms or enzymes6%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium5%
G01NInvestigating or analysing materials by determining their chemical or physical properties4%
C07JSteroids3%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms3%
C40BCombinatorial chemistry2%
PatentTitleYear
10,836,744Diamide compounds having muscarinic receptor antagonist and b2 adrenergic receptor agonist activity202010,792,282Protein kinase C inhibitors and uses thereof202010,780,102Triterpenoids with HIV maturation inhibitory activity202010,774,076Benzazole compounds and methods for making and using the compounds202010,710,9832,4-diamino-pyrimidine compounds and method for making and using the compounds202010,677,787Antibody screening methods202010,604,578PDGF receptor beta binding polypeptides202010,590,107Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity202010,590,121Kinase inhibitors and methods for making and using202010,556,891Compositions and methods for inhibition of the JAK pathway202010,533,055Antibodies and chimeric antigen receptors specific for CD19202010,519,436Methods and compositions for generation of binding agents against cell surface antigens201910,519,438Protein screening methods201910,502,748Method of differentiating stable angina pectoris from acute coronary syndrome and diagnostic kit thereof201910,493,070Azadecalin derivatives as inhibitors of human immunodeficiency virus replication201910,479,783Compositions and methods for inhibition of the JAK pathway201910,421,774C-3 and C-17 modified triterpenoids as HIV-1 inhibitors201910,414,753Amide compounds and method for making and using201910,370,651Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes201910,370,367IRAK inhibitors and method for making and using201910,358,433Diamide compounds having muscarinic receptor antagonist and b2 adrenergic receptor agonist activity2019RE047396Compositions and methods for inhibition of the JAK pathway201910,245,275Triterpenoids with HIV maturation inhibitory activity201910,208,074Pyrazole compounds and method for making and using the compounds201910,208,075Pyrazole compounds and method for making and using the compounds201910,202,462Bi-specific antigen-binding polypeptides201910,196,3592-alkyloxy benzene formyl arylamine compound and pharmaceutical use thereof201910,138,220Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity201810,086,076Interleukin-13 binding proteins201810,065,946Benzazole compounds and methods for making and using the compounds201810,047,118C17-aryl substituted betulinic acid analogs201810,010,552Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer201810,005,767Compositions and methods for inhibition of the JAK pathway201810,005,777Protein kinase C inhibitors and uses thereof20189,982,000Pyrazole compounds and method for making and using the compounds20189,975,875Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity20189,920,041'Compositions and methods for inhibition of the JAK pathway'20189,914,747'Extended betulinic acid analogs'20189,880,160'Antibody screening methods'20189,862,758'Inhibitors of type 2 vascular endothelial growth factor receptors'20189,803,193'Protein screening methods'20179,771,350'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20179,682,957'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20179,682,976'Protein kinase C inhibitors and uses thereof'20179,644,233'Loop-shaped primer used in nucleic acid amplification and the use thereof'20179,636,375'Hepatitis C virus inhibitors'20179,631,016'Pen-injector device containing anti-IL-6 antibodies'20179,611,260'Compositions and methods for inhibition of the JAK pathway'20179,592,293'Interleukin-13 binding proteins'20179,572,802'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20179,566,283'Compositions and methods for inhibition of the JAK pathway'20179,566,278'Protein kinase C inhibitors and uses thereof'20179,527,882'Triterpenoids with HIV maturation inhibitory activity'20169,416,179'PDGF receptor beta binding polypeptides'20169,340,613'Anti-IL-6 antibodies, compositions, methods and uses'20169,328,157'Inhibitors of type 2 vascular endothelial growth factor receptors'20169,321,763'Protein kinase C inhibitors and uses thereof'20169,271,988'Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer'20169,248,132'Compositions and methods for inhibition of the JAK pathway'20169,249,180'C-3 alkyl and alkenyl modified betulinic acid derivatives'20169,227,940'Hepatitis C virus inhibitors'20169,169,249'Protein kinase C inhibitors and uses thereof'20159,134,304'Protein screening methods'20159,084,795'Compositions and methods for inhibition of the JAK pathway'20159,067,925'Compositions and methods for inhibition of the JAK pathway'20159,000,173'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20158,969,571'Biphenyl derivatives'20158,906,889'C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity'20148,889,854'C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity'20148,889,871'Hepatitis C virus inhibitors'20148,846,647'C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity'20148,816,088'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20148,802,661'C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors'20148,748,415'C-28 amines of C-3 modified betulinic acid derivatives as HIV maturation inhibitors'20148,735,400'Compositions and methods for inhibition of the JAK pathway'20148,710,229'Hepatitis C virus inhibitors'20148,623,362'Anti-IL-6 antibodies'20148,609,613'Methods of inhibiting type 2 vascular endothelial growth factor receptors using polypeptides'20138,604,177'Interleukin-13 binding proteins'20138,563,716'Compositions and methods for inhibition of the JAK pathway'20138,563,569'Compositions and methods for inhibition of the JAK pathway'20138,551,978'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20138,530,656'Compositions and methods for inhibition of the JAK pathway'20138,524,901'Compositions and methods for inhibition of the JAK pathway'20138,507,675'Compositions and methods for inhibition of the JAK pathway'20138,343,954'Compositions and methods for inhibition of the JAK pathway'20138,324,362'Nucleic acid encoding 10FN3 polypeptide inhibitors of Type 2 vascular endothelial growth factor receptors'20128,324,200'Compositions and methods for inhibition of the JAK pathway'20128,299,094'Hepatitis C virus inhibitors'20128,226,611'Anti-IL-6 antibodies, compositions, methods and uses'20128,138,345'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20128,067,003'Methods of treating conditions using anti-IL-6 antibodies'20118,062,892'Genes, compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer'20118,008,078'Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins'20117,915,291'Hepatitis C virus inhibitors'20117,915,388'Interleukin-13 binding proteins'20117,879,879'Biphenyl derivatives'20117,858,739'Inhibitors of type 2 vascular endothelial growth factor receptors'20107,858,340'Polynucleotides and methods of directing the ratio of B2:B1 avermectins in Streptomyces avermitilis host cells'20107,846,737'Genes, compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer'20107,847,062'Pharmacokinetic modulation and compositions for modified FN3 polypeptides'20107,833,755'Anti-IL-6 antibody nucleic acid molecules and methods'20107,829,583'Biphenyl derivatives'20107,772,180'Hepatitis C virus inhibitors'20107,560,112'Anti-il-6 antibodies, compositions, methods and uses'20097,557,126'Diphenylmethyl compounds useful as muscarinic receptor antagonists'20097,524,959'Biphenyl derivatives'20097,521,561'Biphenyl derivatives'20097,514,558'Biphenyl derivatives'20097,507,751'Biphenyl derivatives'20097,449,479'Hepatitis C virus inhibitors'20087,388,085'Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins'20087,365,154'Peptides antagonistic to an anti-angiogenic antibody and uses therefor'20087,361,511'Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer'20087,355,046'Biphenyl derivatives'20087,345,175'Biphenyl derivatives'20087,285,564'Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds'20077,250,414'Diphenylmethyl compounds useful as muscarinic receptor antagonists'20077,141,671'Biphenyl derivatives'20067,125,663'Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer'20067,026,118'Pharmaceutical composition containing calcineurin B subunit'20066,995,174'Hepatitis C virus inhibitors'20066,849,608'Macrolide antibiotics'20056,632,673'Directing the ratio of B2:B1 avermectins in Streptomyces avermitilis host cells'20036,420,535'6-O-carbamate ketolide derivatives'20026,124,269'2-Halo-6-O-substituted ketolide derivatives'20006,030,774'Method for introducing defined sequences at the 3\' end of polynucleotides'20005,932,248'Controlled release preparations for cytotoxic or cytostatic drugs'19995,683,879'Methods for producing a single stranded polydeoxynucleotide having two different defined sequences and kits'19975,679,512'Method for introducing defined sequences at the 3\'end of polynucleotides'19975,605,796'Method for preventing amplification of nucleic acid contaminants in amplification mixtures using nuclease-receptor conjugates'1997Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2002–2014Based in Guilford, CT, US· patent location history
2006–2018Patents assigned to BRISTOL MYERS SQUIBB CO (21)· patent assignee history
2006–2014Patents assigned to THERAVANCE INC (15)· patent assignee history
2006–2012Based in Burlingame, CA, US· patent location history
2010–2020Patents assigned to CHEN YAN (29)· patent assignee history
2010–2020Based in Lexington, MA, US· patent location history
2012–2020Patents assigned to RIGEL PHARMACEUTICALS INC (33)· patent assignee history
2013–2020Based in Foster City, CA, US· patent location history
2014–2020Patents assigned to THERAVANCE RESPIRATORY CO LLC (11)· patent assignee history
2014–2020Based in Wallingford, CT, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| RIGEL PHARMACEUTICALS INC | 33 | 2012–2020 |
| CHEN YANself | 29 | 2010–2020 |
| BRISTOL MYERS SQUIBB CO | 21 | 2006–2018 |
| THERAVANCE INC | 15 | 2006–2014 |
| THERAVANCE RESPIRATORY CO LLC | 11 | 2014–2020 |
Locations
| Location | Patents | Span |
|---|---|---|
| Foster City, California, US | 44 | 2013–2020 |
| Lexington, Massachusetts, US | 19 | 2010–2020 |
| Wallingford, CT, US | 14 | 2014–2020 |
| Burlingame, California, US | 14 | 2006–2012 |
| Guilford, CT, US | 10 | 2002–2014 |